Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2011

View Archived Issues

Aliskiren/amlodipine combination shows promise as initial therapy for hypertension

Phase II data presented on sorafenib in GIST and esophageal/gastroesophageal junction cancer

Polypill reduces cardiovascular risk factors in clinical trial

Pfizer develops novel inhibitors of HCV replication

Novel beta-secretase 1 inhibitors claimed at Lilly

Neuropilin-2 promotes epithelial-mesenchymal transition in CRC

CFAK-C4 receives FDA orphan drug status in pancreatic cancer based on preclinical data

First-line TH-302 plus gemcitabine shows promise in advanced/metastatic pancreatic cancer

Receptos begins treatment in phase I trial of RPC-1063 for multiple sclerosis

ALS Biopharma receives ADDF grant to develop HSP70 inducers for AD

Apogenix provides update on phase II APG-101 trial in glioblastoma multiforme

New agents with antidepressant activity claimed by Green Cross

Primary efficacy endpoint met in phase III Gattex trial in short bowel syndrome

DigiFab approved in Canada to treat digoxin toxicity/overdose

New lysophospholipid S1P1 receptor agonists patented

Allergan and MAP Pharma collaborate on Levadex for acute migraine

Vivalis divulges new inhibitors of RNA-directed RNA polymerase

Provectus completes treatment in phase I trial of PV-10 in liver cancer

Nuedexta launched in U.S. for treatment of pseudobulbar affect

Phase I data reported on NRM-8499, a prodrug for Alzheimer's disease

Peregrine fully enrolls phase Ib trial of bavituximab in HIV/HCV coinfection

CHMP recommends approval of BF-200 ALA for actinic keratosis

Onyx initiates rolling NDA for carfilzomib in multiple myeloma

Manhattan Pharma to advance AST-915 to phase II in essential tremor

Phase III trial of Cytotect for prevention of congenital CMV infection to continue

Faron and Maruishi to collaborate on Traumakine program in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...